Prostate cancer drug darolutamide under safety watch in korea

NCT ID NCT06334120

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study monitors the safety and effectiveness of darolutamide (Nubeqa) in 600 Korean men with non-metastatic or metastatic hormone-sensitive prostate cancer. Participants receive the drug as part of their normal care and are followed for one year. Researchers track side effects and how well the drug controls the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: darolutamide (Nubeqa)
What this could lead to: If successful, this study will confirm that darolutamide is safe and works well for Korean men with certain types of prostate cancer.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only includes Korean patients, so findings may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Prostate cancer drug darolutamide under safety watch in korea

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions